Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus bevacizumab for neovascular age-related macular degeneration
2007-005157-33Phase 4Completed
- Sponsor
- Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie
- Start
- Apr 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab, bevacizumab in exudative macular degeneration, sponsored by Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie. Started Apr 2008; status: completed.
02
Drugs
ranibizumabbevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2007-005157-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005157-33.